Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with ...
As a new class of OADs, DPP-4 inhibitors have many important advantages over other currently available antidiabetic drugs. Compared with currently available insulin secretagogues, DPP-4 inhibitors, by ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved JANUMET ® XR ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. NEW ORLEANS — Oral semaglutide, as an add-on to ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...
Merck Receives Positive CHMP Opinion for JANUVIA® (sitagliptin) and JANUMET® (sitagliptin/metformin) as Add-On to Insulin in the European Union WHITEHOUSE STATION ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The DPP-IV inhibitor Januvia does not confer incremental ...
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with ...
The Annals of Pharmacotherapy. 2012;46(6):812-821. Results of DURATION-1 demonstrated significantly greater reductions in A1C and a significantly greater proportion of patients achieving an A1C goal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback